Helix Acquisition Corp. announced the pricing of its $100 million IPO this evening and its shares are expected to begin trading on the Nasdaq under the symbol “HLXA” tomorrow, Tuesday, October 20.
The new company aims to combine with a biotechnology company that has a drug candidate or therapy with compelling data for the next stage in its development. Helix is led by CEO and Chairman Bihua Chen and CFO Jay Scollins.
Total SPAC deal count for 2020 year-to-date is now 145 with $55.42 billion in gross proceeds raised. This offering is expected to close on Thursday, October 22.
Jefferies LLC is serving as sole book running manager for the offering. White & Case LLP and Maples and Calder are serving as Issuer’s Counsel with Kirkland & Ellis LLP serving as Underwriter’s Counsel. WithumSmith+Brown, PC serves as auditor. Continental Stock Transfer & Trust Company LLC is acting as trustee.